Nucleai, Gilead expand AI tissue analysis for drug development

Nucleai and Gilead Sciences have expanded an existing collaboration to apply AI-powered tissue analytics to the development of antibody-drug conjugates, a class of cancer treatments. Under the expanded partnership, Nucleai's artificial intelligence-driven tissue analysis technology will be used to support Gilead's ADC development programs. Antibody-drug conjugates work by combining an antibody—which can target specific cancer cells—with a cytotoxic payload that kills those cells once the antibody binds. The ability to analyze how candidate ADCs interact with tissue is critical to selecting the most promising compounds for clinical testing. By deploying Nucleai's analytical tools, the companies aim to improve their understanding of tissue response and optimize drug candidates accordingly. The partnership represents a strategic move by both organizations to leverage computational approaches in drug discovery and development, though the announcement does not specify financial terms, a completion date, or specific pipeline programs that will benefit from the collaboration.